Cell Metab:给二甲双胍跪了!科学家证实二甲双胍能抑制雾霾引起的动脉血栓,预防心血管疾病的发生

2018-10-17 奇点糕 奇点网

最近,美国西北大学的Scott Budinger教授带来了一个振奋人心的消息!他领导的团队在小鼠中证实,二甲双胍能预防雾霾引起的炎症,阻止免疫细胞释放一种危险分子到血液中,抑制动脉血栓的形成,从而降低心血管疾病的发病风险!

最近,美国西北大学的Scott Budinger教授带来了一个振奋人心的消息!他领导的团队在小鼠中证实,二甲双胍预防雾霾引起的炎症,阻止免疫细胞释放一种危险分子到血液中,抑制动脉血栓的形成,从而降低血管疾病的发病风险!

同时,也有很多证据表明该药在人类中很可能有用,可以作为预防雾霾诱发的血管疾病的潜在药物。这项研究成果发表在近期的顶级学术期刊Cell metabolism上。


Budinger教授

雾霾对于人类健康的影响早已被证实。在发达国家,空气中PM2.5浓度每降低10 mg/m3,人均寿命会增加0.8年。

而在发展中国家,这个问题更加严重。雾霾的一个主要危害在于其能引发严重的缺血性心血管疾病,而心血管疾病正是人类健康的第一大杀手。

作为屡立奇功的神药,二甲双胍的辉煌历史大家也早有所耳闻。作为一种治疗糖尿病的特效药,在全世界已被超过一亿人使用。后来,人们陆续发现二甲双胍可以延缓衰老,延长寿命,抑制肿瘤生长,甚至在免疫治疗中也能发挥作用。被人们冠以“神药”之名。

而Budinger实验室的研究者又给神药增加了一层新的光环。

他们先在小鼠中证明了二甲双胍能抑制雾霾引起的血栓的形成。

在实验中,研究人员先给小鼠服用治疗剂量(100 mg/kg/day)的二甲双胍。24小时后,将小鼠暴露在属于轻度污染的PM2.5(也叫CAP,平均浓度为118.3 ± 5.21 μg/m3)中,连续三天,每天8小时。在第三天,用氯化铁处理小鼠,在小鼠中制造伤害(这是标准的缺血性中风模型)。

检测小鼠颈动脉处的血栓,发现二甲双胍能明显减少小鼠动脉中血栓堵塞的时间,达到了与没有暴露PM2.5的小鼠相当的效果。可见,二甲双胍神药之名绝非浪得虚名!


二甲双胍能明显减少血栓堵塞的时间

PM2.5能诱发血栓的原因在于其能诱发肺部的炎症。

哺乳动物在呼吸中总会吸入灰尘或烟雾等污染颗粒,于是,进化出了一套清理这些颗粒的防御措施。其中,肺泡巨噬细胞和粘膜纤毛能有效清除这些微小颗粒,消除或减少炎症发生。

但是,现在空气中的污染物PM,包括PM2.5,会诱发肺泡巨噬细胞释放促炎性细胞因子IL-6。这个IL-6进入血液循环后,会在肝脏中诱导多种凝血因子的表达,这在小鼠模型中被证明会引发动脉血栓。在针对中国人群中的一项研究中,显示雾霾在人类中也会诱发IL-6的释放。

而小鼠中研究也证明,PM诱导的 IL-6的释放,需要线粒体产生活性氧进行触发。

这篇论文的另一位作者Navdeep 教授,与Budinger教授合作超过二十年,一直致力于研究二甲双胍对线粒体代谢活动的影响。

3年前,Chandel教授证明二甲双胍能减弱线粒体的代谢活动,抑制肿瘤的生长。

受到这项研究的启发,Budinger教授敏锐地察觉到二甲双胍可能可以预防雾霾引发的动脉血栓。

于是就有了上面的小鼠实验。

随后,科研人员继续探索了二甲双胍的作用原理。

通过实验,他们证实了二甲双胍能抑制PM诱导的IL-6的释放。

接着,他们又证明,二甲双胍抑制IL-6释放的原因在于其能抑制线粒体中电子传递链的功能,减少了活性氧的产生。

细胞中活性氧的减少使得钙释放激活通道(CARC)无法发挥作用,而CARC正是PM诱导的IL-6释放所必需的。

由此,研究者们揭示这样一个作用机制,二甲双胍阻碍线粒体电子链,抑制了活性氧的产生,使得CARC无法发挥作用,从而阻断了PM诱导的IL-6的释放,进而抑制动脉血栓的形成。

这个机制得到了遗传学实验的证明。


二甲双胍抑制雾霾引起的血栓的作用机制

由于在人群中的实验已经证明PM会引发IL-6的释放,因而二甲双胍的这个作用在人类中有独特的意义。

当然,作者也表示,要证明二甲双胍能在人类中预防雾霾污染引起的心血管疾病,还需要进行进一步的临床研究进行验证。

不过,早有研究发现,长期服用二甲双胍的糖尿病人心血管疾病的发病风险更小,这与服用二甲双胍的糖尿病人患癌风险减少有异曲同工之妙。这也williamhill asia 增加了对二甲双胍的信心。

二甲双胍在作为一个抗糖尿病药物和抗肿瘤药物后,又被证明是一个抗炎药物。而其独特的抗炎效果可以预防雾霾引发的动脉血栓。这为全世界饱受空气污染的人送来福音,尤其是如今雾霾严重的中国。

同时,二甲双胍的安全性和廉价性也使它能造福更多的人。

凛冬将至,雾霾会更加频繁地来袭,除了口罩和空气净化器,希望二甲双胍也能为williamhill asia 提供了另一层安全保障。

当然,近年来,williamhill asia 已经见证了空气质量的大幅改善,也希望今后生活的环境能越来越好。

原始出处:Saul Soberanes, Alexander V. Misharin, Amit Jairaman, et al. Metformin Targets Mitochondrial Electron Transport to Reduce Air-Pollution-Induced Thrombosis. Cell Metab. 2018 Oct 4.

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1797869, encodeId=ec681e978690d, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Mon Nov 26 23:53:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870929, encodeId=be8718e0929d2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Mar 26 05:53:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708994, encodeId=e8081e08994bc, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Fri Dec 28 07:53:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896395, encodeId=f07a189639561, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Aug 15 00:53:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887946, encodeId=8d52188e946cc, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Aug 14 16:53:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350990, encodeId=59a135099060, content=非常不错的临床经验,学习了,值得借鉴,受益匪浅,感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Tue Oct 30 22:25:37 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961201, encodeId=d385196120111, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jul 21 07:53:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367510, encodeId=382f136e510ca, content=<a href='/topic/show?id=c65e988e336' target=_blank style='color:#2F92EE;'>#雾霾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98873, encryptionId=c65e988e336, topicName=雾霾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498485, encodeId=986d149848556, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536818, encodeId=ef3e15368183a, content=<a href='/topic/show?id=fcbd3332949' target=_blank style='color:#2F92EE;'>#动脉血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33329, encryptionId=fcbd3332949, topicName=动脉血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=715e12724163, createdName=yangcx0919, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1797869, encodeId=ec681e978690d, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Mon Nov 26 23:53:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870929, encodeId=be8718e0929d2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Mar 26 05:53:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708994, encodeId=e8081e08994bc, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Fri Dec 28 07:53:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896395, encodeId=f07a189639561, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Aug 15 00:53:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887946, encodeId=8d52188e946cc, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Aug 14 16:53:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350990, encodeId=59a135099060, content=非常不错的临床经验,学习了,值得借鉴,受益匪浅,感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Tue Oct 30 22:25:37 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961201, encodeId=d385196120111, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jul 21 07:53:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367510, encodeId=382f136e510ca, content=<a href='/topic/show?id=c65e988e336' target=_blank style='color:#2F92EE;'>#雾霾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98873, encryptionId=c65e988e336, topicName=雾霾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498485, encodeId=986d149848556, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536818, encodeId=ef3e15368183a, content=<a href='/topic/show?id=fcbd3332949' target=_blank style='color:#2F92EE;'>#动脉血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33329, encryptionId=fcbd3332949, topicName=动脉血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=715e12724163, createdName=yangcx0919, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1797869, encodeId=ec681e978690d, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Mon Nov 26 23:53:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870929, encodeId=be8718e0929d2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Mar 26 05:53:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708994, encodeId=e8081e08994bc, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Fri Dec 28 07:53:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896395, encodeId=f07a189639561, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Aug 15 00:53:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887946, encodeId=8d52188e946cc, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Aug 14 16:53:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350990, encodeId=59a135099060, content=非常不错的临床经验,学习了,值得借鉴,受益匪浅,感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Tue Oct 30 22:25:37 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961201, encodeId=d385196120111, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jul 21 07:53:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367510, encodeId=382f136e510ca, content=<a href='/topic/show?id=c65e988e336' target=_blank style='color:#2F92EE;'>#雾霾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98873, encryptionId=c65e988e336, topicName=雾霾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498485, encodeId=986d149848556, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536818, encodeId=ef3e15368183a, content=<a href='/topic/show?id=fcbd3332949' target=_blank style='color:#2F92EE;'>#动脉血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33329, encryptionId=fcbd3332949, topicName=动脉血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=715e12724163, createdName=yangcx0919, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1797869, encodeId=ec681e978690d, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Mon Nov 26 23:53:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870929, encodeId=be8718e0929d2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Mar 26 05:53:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708994, encodeId=e8081e08994bc, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Fri Dec 28 07:53:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896395, encodeId=f07a189639561, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Aug 15 00:53:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887946, encodeId=8d52188e946cc, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Aug 14 16:53:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350990, encodeId=59a135099060, content=非常不错的临床经验,学习了,值得借鉴,受益匪浅,感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Tue Oct 30 22:25:37 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961201, encodeId=d385196120111, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jul 21 07:53:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367510, encodeId=382f136e510ca, content=<a href='/topic/show?id=c65e988e336' target=_blank style='color:#2F92EE;'>#雾霾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98873, encryptionId=c65e988e336, topicName=雾霾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498485, encodeId=986d149848556, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536818, encodeId=ef3e15368183a, content=<a href='/topic/show?id=fcbd3332949' target=_blank style='color:#2F92EE;'>#动脉血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33329, encryptionId=fcbd3332949, topicName=动脉血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=715e12724163, createdName=yangcx0919, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=)]
    2019-08-15 一闲
  5. [GetPortalCommentsPageByObjectIdResponse(id=1797869, encodeId=ec681e978690d, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Mon Nov 26 23:53:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870929, encodeId=be8718e0929d2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Mar 26 05:53:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708994, encodeId=e8081e08994bc, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Fri Dec 28 07:53:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896395, encodeId=f07a189639561, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Aug 15 00:53:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887946, encodeId=8d52188e946cc, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Aug 14 16:53:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350990, encodeId=59a135099060, content=非常不错的临床经验,学习了,值得借鉴,受益匪浅,感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Tue Oct 30 22:25:37 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961201, encodeId=d385196120111, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jul 21 07:53:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367510, encodeId=382f136e510ca, content=<a href='/topic/show?id=c65e988e336' target=_blank style='color:#2F92EE;'>#雾霾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98873, encryptionId=c65e988e336, topicName=雾霾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498485, encodeId=986d149848556, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536818, encodeId=ef3e15368183a, content=<a href='/topic/show?id=fcbd3332949' target=_blank style='color:#2F92EE;'>#动脉血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33329, encryptionId=fcbd3332949, topicName=动脉血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=715e12724163, createdName=yangcx0919, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=)]
    2019-08-14 guojianrong
  6. [GetPortalCommentsPageByObjectIdResponse(id=1797869, encodeId=ec681e978690d, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Mon Nov 26 23:53:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870929, encodeId=be8718e0929d2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Mar 26 05:53:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708994, encodeId=e8081e08994bc, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Fri Dec 28 07:53:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896395, encodeId=f07a189639561, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Aug 15 00:53:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887946, encodeId=8d52188e946cc, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Aug 14 16:53:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350990, encodeId=59a135099060, content=非常不错的临床经验,学习了,值得借鉴,受益匪浅,感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Tue Oct 30 22:25:37 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961201, encodeId=d385196120111, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jul 21 07:53:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367510, encodeId=382f136e510ca, content=<a href='/topic/show?id=c65e988e336' target=_blank style='color:#2F92EE;'>#雾霾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98873, encryptionId=c65e988e336, topicName=雾霾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498485, encodeId=986d149848556, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536818, encodeId=ef3e15368183a, content=<a href='/topic/show?id=fcbd3332949' target=_blank style='color:#2F92EE;'>#动脉血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33329, encryptionId=fcbd3332949, topicName=动脉血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=715e12724163, createdName=yangcx0919, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=)]
    2018-10-30 13718711b3m

    非常不错的临床经验,学习了,值得借鉴,受益匪浅,感谢分享!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1797869, encodeId=ec681e978690d, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Mon Nov 26 23:53:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870929, encodeId=be8718e0929d2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Mar 26 05:53:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708994, encodeId=e8081e08994bc, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Fri Dec 28 07:53:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896395, encodeId=f07a189639561, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Aug 15 00:53:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887946, encodeId=8d52188e946cc, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Aug 14 16:53:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350990, encodeId=59a135099060, content=非常不错的临床经验,学习了,值得借鉴,受益匪浅,感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Tue Oct 30 22:25:37 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961201, encodeId=d385196120111, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jul 21 07:53:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367510, encodeId=382f136e510ca, content=<a href='/topic/show?id=c65e988e336' target=_blank style='color:#2F92EE;'>#雾霾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98873, encryptionId=c65e988e336, topicName=雾霾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498485, encodeId=986d149848556, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536818, encodeId=ef3e15368183a, content=<a href='/topic/show?id=fcbd3332949' target=_blank style='color:#2F92EE;'>#动脉血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33329, encryptionId=fcbd3332949, topicName=动脉血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=715e12724163, createdName=yangcx0919, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=)]
    2019-07-21 维他命
  8. [GetPortalCommentsPageByObjectIdResponse(id=1797869, encodeId=ec681e978690d, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Mon Nov 26 23:53:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870929, encodeId=be8718e0929d2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Mar 26 05:53:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708994, encodeId=e8081e08994bc, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Fri Dec 28 07:53:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896395, encodeId=f07a189639561, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Aug 15 00:53:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887946, encodeId=8d52188e946cc, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Aug 14 16:53:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350990, encodeId=59a135099060, content=非常不错的临床经验,学习了,值得借鉴,受益匪浅,感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Tue Oct 30 22:25:37 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961201, encodeId=d385196120111, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jul 21 07:53:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367510, encodeId=382f136e510ca, content=<a href='/topic/show?id=c65e988e336' target=_blank style='color:#2F92EE;'>#雾霾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98873, encryptionId=c65e988e336, topicName=雾霾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498485, encodeId=986d149848556, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536818, encodeId=ef3e15368183a, content=<a href='/topic/show?id=fcbd3332949' target=_blank style='color:#2F92EE;'>#动脉血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33329, encryptionId=fcbd3332949, topicName=动脉血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=715e12724163, createdName=yangcx0919, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=)]
    2018-10-18 chenshujs
  9. [GetPortalCommentsPageByObjectIdResponse(id=1797869, encodeId=ec681e978690d, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Mon Nov 26 23:53:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870929, encodeId=be8718e0929d2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Mar 26 05:53:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708994, encodeId=e8081e08994bc, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Fri Dec 28 07:53:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896395, encodeId=f07a189639561, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Aug 15 00:53:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887946, encodeId=8d52188e946cc, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Aug 14 16:53:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350990, encodeId=59a135099060, content=非常不错的临床经验,学习了,值得借鉴,受益匪浅,感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Tue Oct 30 22:25:37 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961201, encodeId=d385196120111, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jul 21 07:53:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367510, encodeId=382f136e510ca, content=<a href='/topic/show?id=c65e988e336' target=_blank style='color:#2F92EE;'>#雾霾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98873, encryptionId=c65e988e336, topicName=雾霾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498485, encodeId=986d149848556, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536818, encodeId=ef3e15368183a, content=<a href='/topic/show?id=fcbd3332949' target=_blank style='color:#2F92EE;'>#动脉血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33329, encryptionId=fcbd3332949, topicName=动脉血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=715e12724163, createdName=yangcx0919, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1797869, encodeId=ec681e978690d, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Mon Nov 26 23:53:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870929, encodeId=be8718e0929d2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Mar 26 05:53:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708994, encodeId=e8081e08994bc, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Fri Dec 28 07:53:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896395, encodeId=f07a189639561, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Aug 15 00:53:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887946, encodeId=8d52188e946cc, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Aug 14 16:53:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350990, encodeId=59a135099060, content=非常不错的临床经验,学习了,值得借鉴,受益匪浅,感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Tue Oct 30 22:25:37 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961201, encodeId=d385196120111, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jul 21 07:53:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367510, encodeId=382f136e510ca, content=<a href='/topic/show?id=c65e988e336' target=_blank style='color:#2F92EE;'>#雾霾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98873, encryptionId=c65e988e336, topicName=雾霾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498485, encodeId=986d149848556, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536818, encodeId=ef3e15368183a, content=<a href='/topic/show?id=fcbd3332949' target=_blank style='color:#2F92EE;'>#动脉血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33329, encryptionId=fcbd3332949, topicName=动脉血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=715e12724163, createdName=yangcx0919, createdTime=Thu Oct 18 15:53:00 CST 2018, time=2018-10-18, status=1, ipAttribution=)]

相关威廉亚洲官网

雾霾的危害到底有多大?你的认识或许远远不够

自2013年冬起,雾霾的足迹已经遍布全国。当雾霾侵入williamhill asia 的视野,各种雾霾照片也开始侵占williamhill asia 的朋友圈,人们纷纷拍下雾霾照片,开始秀自己周围如“仙境”的“自然风光”。然而williamhill asia 对这种异常天气现象认识足够吗?通过柴静自费拍摄的《穹顶之下》纪录片,williamhill asia 看到了她自己背着收集器一天的实验以及对肺癌患者的采访录像,直观的看到那些能在williamhill asia 体内沉积的小黑块,williamhill asia 知道雾霾是潜伏着的杀手。然而这样的认知也只是浅表层的了解

重磅!为治理雾霾 6省28市药企或全部停产

环保部出大动作:冬天取暖季,药企或被全部关停!

李克强:集中攻克雾霾成因 该花多少钱就花

“今年财政预算已经做完了,那williamhill asia 就从总理预备费中出这个钱!”李克强说,“williamhill asia 常说钱要花到刀刃上,这件事就是广大人民群众最急切盼望解决的事之一,该花多少钱就花多少钱!”

老年痴呆和“霾”有关?一文了解大脑门户如何被打开

BBC 说“英国每年死于空气污染的人数大约是50 000 人”。而 Maher 教授证明空气污染中的磁性纳米颗粒,可以进入人的大脑。她引用其他证据表明,这些颗粒可能和老年痴呆症 (AD) 相关。

复旦、CDC全新文章:PM2.5污染增加呼吸道疾病的死亡率

复旦大学和中国疾病预防控制中心的研究人员开展了一项大型的流行病学研究。他们发现,随着272个中国城市的细颗粒物空气污染的增加,心血管和呼吸道疾病的死亡率也在增加。他们近日在《美国呼吸道与危重护理学杂志》上发表了这一成果。

Chest:雾霾与烟雾下的生存:**干预可行否?

目前,尽管地区政府机构在不断努力,但是,空气污染仍然是全球公共卫生的重大威胁。2017年1月,伦敦出现了类似于1960年发生的伦敦雾的严重烟雾爆发事件。中国的雾霾也在北京出现,其中PM2.5(特别是小于2.5微米)的水平甚至高达500微克/立方米。欧洲地区烟雾和中国地区的阴霾每年都导致大量的过早死亡,其发生率分别为40万和120万,其中主要是由于呼吸系统疾病、脑血管疾病和缺血性心脏病。除了空气污染